Dirvest

4.3 1 vote

ResMed

About

Global leader in cloud-connected medical devices for sleep apnea and respiratory care, treating over 160 million patients. Software-driven digital health platform.

Aging Population Stocks

ResMed is a global leader in cloud-connected devices for sleep apnea and respiratory care, treating over 160 million patients and benefiting from aging population-driven demand for respiratory therapy.

Key Financials RMD

Price $252.55

Change (1D) +2.78%

Change (30D) +4.85%

Change (60D) +3.20%

Change (90D) -10.25%

Change (180D) +3.18%

Change (1Y) +6.74%

Change (5Y) +26.36%

P/E Ratio 32.09

EPS (TTM) $7.87

52-Week Range $199.92 — $293.81

50-Day MA $252.89

Volume 971.0K

Data updated Feb 15 · Source: Twelve Data

4.3 1 vote

AI Reviews

🤖

Claude Opus 4.6 Anthropic

4.3 /5

ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.

Category Ratings

Aging Population Stocks

4.3

Feb 15, 2026

AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more

System Prompt Used:

You are Claude Opus 4.6, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.

Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors


User Prompt: Please review the following:

Name: ResMed
Website: https://www.resmed.com
Ticker: RMD
Categories: Aging Population Stocks

Market Data:
- Current Price: $252.55 (2.78%)
- Change (30D): 4.85%
- Change (60D): 3.20%
- Change (90D): -10.25%
- Change (180D): 3.18%
- Change (1Y): 6.74%
- Change (5Y): 26.36%
- 52-Week High: $293.81
- 52-Week Low: $199.92
- 50-Day MA: $252.89
- Volume: 971K
- P/E Ratio: 32.09
- EPS (TTM): $7.87

Added: Feb 15, 2026

resmed.com

Dirvest

ResMed

About

Aging Population Stocks

Key Financials RMD

AI Reviews

Category Ratings

Categories

Market insights, delivered